Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling ...

A new study finds the use of weight loss drugs like Ozempic, Wegovy, and Zepbound in people with Type-1 Diabetes has risen ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Opinion: McDermott, Will & Emery's Byron Kalogerou and Meredith Cullen Schwartz say demand in the anti-obesity market and new ...

U.S. President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government's Medicare program. The Centers for Medicare and ...

Joe Biden had proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and ... and other serious health issues. The federal program ...

Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy. The rule was not expected to be ...

Wegovy and Zepbound both cost roughly $1,000 before insurance and other rebates. Allowing Medicare to cover those drugs and other weight loss medications could cost $35 billion over nine years ...